Breaking News Instant updates and real-time market news.

FPRX

Five Prime

$29.72

0.44 (1.50%)

16:24
07/17/17
07/17
16:24
07/17/17
16:24

Five Prime starts dosing in trial evaluating FPA144 in Gastric Cancer in Japan

Five Prime Therapeutics announced the company has initiated dosing in its Phase 1 clinical trial of FPA144, an anti-FGF receptor 2b antibody, in patients with advanced gastric and gastroesophageal cancer in Japan."Gastric cancer is the sixth most common cancer by incidence globally and we estimate approximately 10% of gastric cancer patients have tumors that have FGFR2 gene amplification or overexpress FGFR2b, which are associated with significantly lower survival rates than the gastric cancer patient population as a whole," said Helen Collins, M.D., Senior Vice President and Chief Medical Officer of Five Prime. "Moreover, the observed incidence of gastric cancer is higher in Asian populations than in other populations. We believe FPA144 represents a potentially promising treatment option for this targeted patient population with high unmet need. "The number of metastatic gastric and gastroesophageal junction cancer patients eligible for front-line treatment in Japan is approximately 73,000 patients per year. Five Prime estimates approximately 7,300 patients per year could be biomarker-positive and eligible for FPA144 treatment with front-line chemotherapy. The Phase 1 open-label, dose-finding study will evaluate the safety, tolerability, pharmacokinetics and recommended dose of FPA144 in approximately 6 to 12 Japanese patients with advanced gastric or gastroesophageal cancer. Completion of this Phase 1 trial is intended to enable the inclusion of Japanese patients in potential future Phase 3 trials of FPA144 in gastric cancer. Internal non-clinical data demonstrates additivity of FPA144 to standard-of-care chemotherapy regimens. Five Prime plans to initiate a global pivotal trial of FPA144 for front-line treatment of FGFR2b-overexpressing or FGFR2 gene-amplified metastatic gastric and gastroesophageal junction cancer in combination with chemotherapy in 2018.

FPRX Five Prime
$29.72

0.44 (1.50%)

03/24/17
COWN
03/24/17
INITIATION
COWN
Outperform
Five Prime initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani initiated Five Prime (FPRX) with an Outperform saying its proprietary IO platform is underappreciated by investors and has multiple clinical readouts in 2017 provide catalysts to drive value generation. The analyst said Five Prime's $1.8B out-licensing partnership deal with Bristol Myers (BMY) for Cabiralizumab in 2015 provides validation in supporting its platform.
03/01/17
NOMU
03/01/17
INITIATION
Target $94
NOMU
Buy
Five Prime initiated with a Buy at Nomura
Nomura initiated Five Prime with a Buy and a $94 price target.
10/25/16
SBSH
10/25/16
INITIATION
Target $65
SBSH
Buy
Five Prime initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Five Prime Therapeutics with a Buy rating and $65 price target. The company has "multiple shots" on goal in various cancers, Karnauskas tells investors in a research note. She believes investors will assign higher value to the Cabiralizumab program once combo data with Opdivo is seen in 2017. The analyst sees fair value for Five Prime shares in the $65-$80 range.
08/09/16
WELS
08/09/16
NO CHANGE
WELS
Five Prime weakness overdone, says Wells Fargo
After a trial of the OPDIVO cancer treatment of Five Prime's (FPRX) partner, Bristol Myers Squibb (BMY), showed disappointing results, Wells Fargo thinks that the nearly 9% decline in Five Prime's stock was overdone. The firm thinks that it's "premature" to determine that Merck's (MRK) Keytruda has overtaken OPDIVO. The firm believes that Five Prime's OPDIVO can redeem itself in upcoming studies, and it thinks that Five Prime's stock can advance if the actor-1 receptor is proven to be a worthwhile target ,whether or not OPDIVO is shown to be effective. The firm keeps an Outperform rating on Five Prime.

TODAY'S FREE FLY STORIES

GOOGL

Alphabet Class A

$969.03

-29.28 (-2.93%)

14:31
07/26/17
07/26
14:31
07/26/17
14:31
Recommendations
Alphabet Class A analyst commentary  »

Alphabet recent weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$32.95

0.32 (0.98%)

14:30
07/26/17
07/26
14:30
07/26/17
14:30
Options
Sizable spread in SPDR Oil Exploration and Production ETF »

Sizable spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:30
07/26/17
07/26
14:30
07/26/17
14:30
General news
FOMC takeaway: there was one subtle shift in the Fed's statement »

FOMC takeaway: there was…

YY

YY

$73.02

2.33 (3.30%)

14:25
07/26/17
07/26
14:25
07/26/17
14:25
Options
YY call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

14:25
07/26/17
07/26
14:25
07/26/17
14:25
General news
FX Action: The dollar »

FX Action: The dollar…

14:20
07/26/17
07/26
14:20
07/26/17
14:20
General news
Treasury Action: yields whipsawed in the wake of the FOMC »

Treasury Action: yields…

ABX

Barrick Gold

$16.00

-0.04 (-0.25%)

14:20
07/26/17
07/26
14:20
07/26/17
14:20
Technical Analysis
Technical Earnings Preview: Barrick Gold range-bound before earnings »

Shares have been marking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

AMZN

Amazon.com

$1,039.87

0.92 (0.09%)

, ULTA

Ulta Beauty

$256.61

4.53 (1.80%)

14:18
07/26/17
07/26
14:18
07/26/17
14:18
Hot Stocks
Piper says Amazon not near-term threat to Ulta Beauty »

Shares of Ulta Beauty…

AMZN

Amazon.com

$1,039.87

0.92 (0.09%)

ULTA

Ulta Beauty

$256.61

4.53 (1.80%)

EL

Estee Lauder

$98.85

0.1 (0.10%)

FB

Facebook

$165.28

-0.72 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 13

    Sep

WEC

WEC Energy

$62.56

0.38 (0.61%)

14:17
07/26/17
07/26
14:17
07/26/17
14:17
Earnings
WEC Energy sees Q3 EPS 63c-67c, consensus 72c »

Says guidance assumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

$NYE

NYSE Market Internals

14:16
07/26/17
07/26
14:16
07/26/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
07/26/17
07/26
14:15
07/26/17
14:15
General news
FOMC held rates steady and gave no firm date on the balance sheet unwind »

FOMC held rates steady…

SQM

SQM

$39.35

0.31 (0.79%)

14:10
07/26/17
07/26
14:10
07/26/17
14:10
Options
Call buyers opening a notable new position in Chemical and Mining of Chile »

Call buyers opening a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:05
07/26/17
07/26
14:05
07/26/17
14:05
General news
Federal Reserve says inflation declined and running below 2% »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
07/26/17
07/26
14:05
07/26/17
14:05
General news
ECB's Nowotny agrees with Weidmann »

ECB's Nowotny agrees…

UMC

UMC

$2.45

-0.11 (-4.30%)

14:02
07/26/17
07/26
14:02
07/26/17
14:02
Downgrade
UMC rating change  »

UMC downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:02
07/26/17
07/26
14:02
07/26/17
14:02
General news
Fed says stance of monetary policy 'remains accommodative' »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:01
07/26/17
07/26
14:01
07/26/17
14:01
General news
Fed sees balance sheet normalization 'relatively soon' »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:01
07/26/17
07/26
14:01
07/26/17
14:01
General news
FOMC Meeting Announcement Federal Funds Rate data reported »

FOMC Meeting Announcement…

SPX

S&P 500

14:00
07/26/17
07/26
14:00
07/26/17
14:00
General news
Breaking General news story on S&P 500 »

Federal Reserve leaves…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBS

RBS

$6.67

0.04 (0.60%)

13:58
07/26/17
07/26
13:58
07/26/17
13:58
Hot Stocks
RBS provides update on remaining State Aid obligation regarding Williams & Glyn »

Following the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$112.70

-0.52 (-0.46%)

, FDX

FedEx

$214.34

-0.03 (-0.01%)

13:50
07/26/17
07/26
13:50
07/26/17
13:50
Earnings
On The Fly: What to watch in UPS earnings report »

UPS (UPS) is scheduled to…

UPS

UPS

$112.70

-0.52 (-0.46%)

FDX

FedEx

$214.34

-0.03 (-0.01%)

BA

Boeing

$229.76

17.3 (8.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 07

    Aug

  • 21

    Aug

GG

Goldcorp

$13.56

0.14 (1.04%)

13:50
07/26/17
07/26
13:50
07/26/17
13:50
Options
Defensive option play in GoldCorp ahead of earnings »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FCEL

FuelCell

$1.48

0.03 (2.07%)

13:50
07/26/17
07/26
13:50
07/26/17
13:50
Hot Stocks
Breaking Hot Stocks news story on FuelCell 

FuelCell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$11.06

-0.215 (-1.91%)

13:48
07/26/17
07/26
13:48
07/26/17
13:48
Hot Stocks
Ford drops after quarterly beat attributed to tax credits »

Shares of car giant Ford…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 01

    Aug

FB

Facebook

$165.28

-0.72 (-0.43%)

13:45
07/26/17
07/26
13:45
07/26/17
13:45
Periodicals
Facebook TV episodes ready for Mid-August, Bloomberg reports »

Facebook has asked…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 13

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.